Use of pulmonary arterial hypertension therapies in patient swith sarcoidosis-associated pulmonary hypertension

Main Article Content

Laura C Price
Vaileios Kouranos
Robert Baughman
Chloe Bloom
Iain Stewart
Oksana Shlobin
Steven Nathan
Konstantinos Dimopoulos
Jonathan Falconer
Rohit Gupta
Colm McCabe
Chinthaka Samaranayake
Thomas Mason
Bhashkhar Mukherjee
Catherine Taube
Ankita Sahni
Aleksander Kempny
Thomas Semple
Elizabetta Renzoni
Athol Wells
S John Wort


Abstract 325 | PDF Downloads 225


1. Lawrie A, Hamilton N, Wood S, Exposto F, Muzwidzwa R, Raiteri L, et al. Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension. Pulm Circ. 2022;12(4):e12136.
2. Shlobin OA, Kouranos V, Barnett SD, Alhamad EH, Culver DA, Barney J, et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J. 2020;55(5).
3. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138(5):1078-85.
4. Samaranayake CB, McCabe C, Wort SJ, Price LC. Sarcoidosis associated pulmonary hypertension: an update. Curr Opin Pulm Med. 2021;27(5):285-95.
5. Savale L, Huitema M, Shlobin O, Kouranos V, Nathan SD, Nunes H, et al. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev. 2022;31(163).
6. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014;145(4):810-7.
7. Baughman RP, Shlobin OA, Gupta R, Engel PJ, Stewart JI, Lower EE, et al. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial. Chest. 2022;161(2):448-57.
8. "2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)." Nazzareno Galie, Marc Humbert, Jean-Luc Vachiery, Simon Gibbs, Irene Lang, Adam Torbicki, Gerald Simonneau, Andrew Peacock, Anton Vonk Noordegraaf, Maurice Beghetti, Ardeschir Ghofrani, Miguel Angel Gomez Sanchez, Georg Hansmann, Walter Klepetko, Patrizio Lancellotti, Marco Matucci, Theresa McDonagh, Luc A. Pierard, Pedro T. Trindade, Maurizio Zompatori and Marius Hoeper. Eur Respir J 2015; 46: 903-975. Eur Respir J. 2015;46(6):1855-6.
9. Boucly A, Cottin V, Nunes H, Jais X, Tazi A, Prevot G, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017;50(4).
10. Abston E, Hon S, Lawrence R, Berman J, Govender P, Farber HW. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):234-8.